MEDRAD launches VirtualCARE solution for Intego PET Infusion System

MEDRAD, Inc. a business of Bayer HealthCare, today announces the U.S. launch of VirtualCARE®, for the MEDRAD Intego™ PET Infusion System. VirtualCARE is a technology platform that allows MEDRAD to remotely support maintenance and system updates securely over the internet.

MEDRAD is the first company in the U.S. to offer remote service and system support for an injection or infusion system.  Utilizing advanced encryption technology, MEDRAD can now provide remote troubleshooting capabilities and system updates for Intego through VirtualCARE.  The VirtualCARE solution has been designed for high performance and security at every level of its architecture, offering customers the potential for faster response time and reduced downtime.

VirtualCARE comes to the market two years after the launch of MEDRAD's Intego. Since its release in 2008, Intego has been placed in hospitals and clinics throughout the U.S., Europe, Australia and the Middle East. The Intego system is loaded with a multi-dose vial of 18F-FDG or 18F-NaF and nuclear medicine technologists can dose on demand from a touchscreen to enable precise, flexible, safe, and efficient administration of the radiopharmaceutical. VirtualCARE is the next step for MEDRAD to enhance service and support capabilities for the Intego PET Infusion System.

"MEDRAD is excited to offer the VirtualCARE technology to support one of our newest and quickly growing platforms with this initial launch for Intego," said Diane Watson, executive director of service commercialization for MEDRAD.  "We are also looking to the future when the VirtualCARE technology can be utilized to support other MEDRAD product platforms in Radiology and Cardiology around the world."